Anastrozole — Drug Intelligence | 47 EU Trials

Filter these 47 trials by condition, phase, country and more.

Open in Search →

47 Registered trials

20 Recruiting

21 Completed trials

28 Sponsors

23 Countries

Phase III

Phase II

Phase III: 28 Phase II: 12 Phase III/IV: 2 Phase IV: 4 Phase I (Other): 1

Oversight events:

1 temporary halt 1 unexpected event 1 corrective measure across 3 trials

View oversight register →

Indications tested

Hormone receptor positive HER2 negative breast cancer 6 Breast cancer 4 Hormone receptor positive breast cancer 2 Hormone refractory breast cancer 1 Hormone receptor negative HER2 positive breast cancer 1 Hormone receptor positive HER2 positive breast cancer 1 HER2 positive breast cancer 1 Breast cancer metastatic 1 Triple positive breast cancer 1 Breast cancer female 1

Sponsors using this IMP

Unicancer 7 AstraZeneca AB 6 Eli Lilly & Co. 3 Cancer Trials Ireland 2 European Organisation For Research And Treatment Of Cancer 2 F. Hoffmann-La Roche AG 2 Fundacion Grupo Espanol De Investigacion En Cancer De Mama 2 Novartis Pharma AG 2 Region Oerebro Laen 2 Alliance Foundation Trials LLC 1 Amsterdam UMC Stichting 1 BOOG Study Center B.V. 1

All trials

47 total

A phase III study comparing the concurrent versus the sequential administration of chemotherapy and aromatase inhibitors, as adjuvant treatm… Pending

2024-519087-41-00 Phase III 1 country IRCCS Ospedale Policlinico San Martino
Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Pending

2024-519655-28-00 Phase III 7 countries Unicancer
SPatial Heterogeneity of INtratumoral drug distribution Pending

2025-520530-32-00 Phase IV 1 country Amsterdam UMC Stichting
A Study of LY4064809 With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) Pending

2025-522791-92-00 Phase III 6 countries Eli Lilly & Co.
Impact of EXercise on quality of life of early breast cancer patients on treatment with adjuvant Aromatase Inhibitors with or without CDK4/6… Pending

2025-522848-40-00 Phase IV 1 country Fundacion Grupo Espanol De Investigacion En Cancer De Mama
Skipping Hormone Therapy in Low-Risk Early Breast Cancer Pending

2025-523683-20-00 Phase II 1 country Unicancer
NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting

2025-520979-13-00 Phase III 5 countries Unicancer
A PHASE 2 STUDY TO RESEARCH THE SAFETY AND EFFICACY OF TRASTUZUMAB DERUXTECAN VERSUS CDK4/6I PLUS ENDOCRINE THERAPY IN ADVANCED BREAST CANCE… Recruiting

2024-512360-55-00 Phase II 9 countries Medica Scientia Innovation Research S.L.
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting

2022-501007-28-00 Phase III 16 countries Eli Lilly & Co.
Optimizing endocrine treatment > 5 years after surgery for breast cancer patients: a registry-based randomized clinical trial Recruiting

2023-506135-14-00 Phase III/IV 1 country Region Oerebro Laen
ABCSG 63 / ERIKA: Elacestrant and RIbociclib in Ki67-tested endocrine responsive breAst cancer: An open-label, two-arm, randomized, phase I… Recruiting

2023-505758-17-00 Phase II 2 countries Verein Zur Praevention Und Therapie Boesartiger Erkrankungen Austrian Breast And…
A trial to learn how well saruparib with camizestrant works and how safe it is in adults with advanced breast cancer that is hormone recepto… Recruiting

2023-504180-16-00 Phase III 10 countries AstraZeneca AB
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C… Recruiting

2024-515445-42-00 Phase III 15 countries Stemline Therapeutics Inc.
Evaluating how well and how safely Alisertib works with hormone therapy in treating patients with breast cancer that has come back or spread… Recruiting

2024-511497-79-00 Phase II 2 countries Puma Biotechnology Inc.
The RED FLASH study Recruiting

2023-507847-13-00 Phase III 1 country Reinier de Graaf Groep
A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment i… Recruiting

2023-508204-38-00 Phase III 9 countries Verastem Inc.
STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C… Recruiting

2023-505871-63-00 Phase III 13 countries Olema Pharmaceuticals Inc.
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 Phase III 16 countries AstraZeneca AB
An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi… Recruiting

2022-501453-36-00 Phase III 11 countries European Organisation For Research And Treatment Of Cancer
IMPlementing geriatric assessment for dose Optimization of CDK 4/6-inhibitors in older bReasT cAncer patieNTs – a pragmatic randomized-contr… Recruiting

2023-506620-87-00 Phase III/IV 6 countries Region Oerebro Laen
Discontinuation of CDK4/6 inhibitors in patients with metastatic HR positive, HER2 negative breast cancer with durable disease control: A ra… Recruiting

2023-504141-31-00 Phase II 1 country Institut fuer Klinische Krebsforschung IKF GmbH
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for SC use) versus plac… Recruiting

2022-502046-28-00 Phase III 7 countries F. Hoffmann-La Roche AG
TRAK-ER_A randomised trial of early detection of molecular relapse with circulating tumour DNA tracking and treatment with palbociclib plus … Recruiting

2024-517414-15-00 Phase II 1 country The Royal Marsden NHS Foundation Trust
CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCE… Recruiting

2022-500764-35-00 Phase IV 1 country Institut Für Frauengesundheit GmbH

Showing 1–24 of 47 trials

← All drugs A–Z